Histologie des Primärtumors und Metastasenverhalten Implikationen für den Radioonkologen anhand von Beispielen

Rhomberg, Walter

doi:10.1007/pl00002328

Cited by 2 publications

(1 citation statement)

References 49 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In den untersuchten Jahrgängen gab es 14 Publikationen mit nur einem einzigen Autor [21,36,38,66,69,80,86,88,100,111,117,135,141,158]. Insgesamt 20 Publikationen hatten zwei Autoren [8,9,28,37,50,65,78,103,109,114,116,123,124,148,149,150,151,157,163,164], 21 Publikationen drei Autoren [6,20,35,40,41,42,43,52,70,73,74,75,112,122,126,127,132,…”

Section: Analyse Der Zeitschrift "Strahlentherapie Und Onkologie" (Jaunclassified

Autorenschaft wissenschaftlicher Veröffentlichungen Analyse der Zeitschrift “Strahlentherapie und Onkologie”

Dubben¹,

Beck‐Bornholdt²,

Schmidt³

2001

Strahlenther Onkol

View full text Add to dashboard Cite

show abstract

Section: Analyse Der Zeitschrift "Strahlentherapie Und Onkologie" (Jaunclassified

Autorenschaft wissenschaftlicher Veröffentlichungen Analyse der Zeitschrift “Strahlentherapie und Onkologie”

Dubben¹,

Beck‐Bornholdt²,

Schmidt³

2001

Strahlenther Onkol

View full text Add to dashboard Cite

show abstract

Role of multimodal treatment in oropharynx, larynx, and hypopharynx cancer

Rudat

Wannenmacher

2001

Seminars in Surgical Oncology

View full text Add to dashboard Cite

Due to recent advances in radiation fractionation, radiochemotherapy, and conservative surgical techniques, the concept of multimodal therapy in head and neck cancer is currently changing. The recently published RTOG Phase III trial 9003, with 1,113 patients accrued, showed that hyperfractionation and accelerated fractionation with concomitant boost are more efficacious than standard fractionation for locally-advanced head and neck cancer. Acute, but not late, toxicity was also increased. Three meta-analyses have suggested that the impact of chemotherapy in head and neck cancer is small but is highly associated with the timing of therapy. Concomitant administration of radiation therapy and chemotherapy led to an absolute benefit in 5-year survival of about 10%. This finding has been further supported by recently published randomized prospective trials comparing concomitant radiochemotherapy with radiotherapy alone in advanced head and neck cancer. There is now clear evidence that radiochemotherapy provides a substantial and statistically significant improvement in survival and local-regional control, as compared to radiotherapy alone. Radiochemotherapy should be considered an accepted standard of care in cancers of the oropharynx, particularly for patients with locally-advanced disease who have a good performance status. Two randomized studies conducted by the Department of Veterans' Affairs and the EORTC, with a total of 534 patients accrued, showed that induction chemotherapy followed by radiotherapy of responders yields survival rates equal to those of total laryngectomy with postoperative radiotherapy. After 4 years, one-half to two-thirds of survivors of the chemotherapy arm retained a functional larynx. Larynx preservation using induction chemotherapy can now be regarded as feasible but still investigational. Current phase II studies show excellent larynx preservation rates using a primary concomitant radiochemotherapy with an altered fractionation regimen. More clinical and laboratory research is required to further evaluate the different treatment options of the multimodality concept, and to develop prognostic models that will allow individualization of the therapy.

show abstract

Histologie des Primärtumors und Metastasenverhalten Implikationen für den Radioonkologen anhand von Beispielen

Cited by 2 publications

References 49 publications

Autorenschaft wissenschaftlicher Veröffentlichungen Analyse der Zeitschrift “Strahlentherapie und Onkologie”

Autorenschaft wissenschaftlicher Veröffentlichungen Analyse der Zeitschrift “Strahlentherapie und Onkologie”

Role of multimodal treatment in oropharynx, larynx, and hypopharynx cancer

Contact Info

Product

Resources

About